Navigation Links
Spectranetics to Present at The A.G Edwards Growth Conference on September 18
Date:9/11/2007

COLORADO SPRINGS, Colo., Sept. 11 /PRNewswire-FirstCall/ -- Spectranetics Corporation (Nasdaq: SPNC) today announced that it will present at the A.G. Edwards Growth Conference, which is being held September 18-19 at the New York Palace Hotel.

John G. Schulte, Spectranetics' president and chief executive officer, is scheduled to speak on Tuesday, September 18, at 9:30 a.m. Eastern time (7:30 a.m. Mountain time) and will discuss the Company's strategic initiatives, product pipeline and market opportunities.

Interested parties can access a live audio webcast and slide presentation at http://www.spectranetics.com. An archived presentation will be available on the Web site for 14 days.

About Spectranetics

Founded in 1984, Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by photo-ablating multiple lesion types into tiny particles that are easily absorbed into the blood stream. The Company's disposable catheters use high-energy "cool" ultraviolet light to vaporize arterial blockages in the legs and heart, as well as scar tissue encapsulating pacing and defibrillation leads. For more information visit http://www.spectranetics.com.

COMPANY CONTACT: INVESTOR & MEDIA CONTACTS:

Spectranetics Corporation Lippert/Heilshorn & Associates, Inc.

Guy Childs, Chief Financial Officer Bruce Voss or Don Markley

(719) 633-8333 (310) 691-7100

'/>"/>

SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...hers from Monash University, The Brigham and Women...anda Pharmaceuticals has found a new drug with the...s caused by shift work. , Dr Shantha Rajaratnam...ychiatry and Psychological Medicine said tasimelte...e brain, could be a highly effective treatment for...
(Date:12/2/2008)...ylol have a higher death risk, data review finds ,...A new study casts more doubt on the safety of the ...in patients undergoing surgery. , Trasylol is a...ates, where it was removed from the market in 2007...esearchers reviewed findings from 49 randomized cl...
(Date:12/2/2008).... 2 Seniors, disabled,...anies gathered today to,oppose efforts by Blue Cr...n,through the lame duck session of the Legislatur...th for many of us in Michigan," said,RoAnne Chane...ty Rights,Coalition. "A vote for this bill is a v...
(Date:12/2/2008)...are injuries accounted for 3.5 percent of high sch...g to the first study to examine rare injuries and ...ries include eye injuries, dental injuries, neck a...ess, which may result in high morbidity, costly su...es. , Football was associated with the highest r...
Breaking Medicine News(10 mins):Health News:New medication brings hope of jet lag cure 2Health News:Another Study Warns of Risk From Cardiac Surgery Drug 2Health News:Opposition Continues to Grow to Blues' Legislation 2Health News:Opposition Continues to Grow to Blues' Legislation 3
...niversity scientists led by Thomas Carpenter, find...supplements for girls, as their effects// would be...entists carried out a trial on 120 girls aged 8 to...gnesium supplements of 300 mg dose and others on a...
...85 more dispensaries by 2010 to provide better hea...shit said Thursday.// She said 365 dispensaries w...nics would be set up soon to "enable the common me...at their doorsteps". The chief minister said her...
...is prone to breast cancer in India, yet the number...ause of the prohibitive costs. But as// another Wo...r such people - Breast Cancer Patients Benefit Fou...inancial help. It is the brainchild of Sameer Kau...
...ays a crucial role in shaping a hollow sphere of s...d. It seems to help in organizing// tissues by dir...They found that in the first few days of life, cer...m the primitive ectoderm from which embryonic tiss...
Other Medicine News:Health News:Funds and Hope for Breast Cancer Patients 2Health News:Ceramide Directs Stem Cells in Embryo 2
(Date:12/1/2008)...APORE, Dec. 1 S*BIO Pte Ltd today ...rial of SB1518, a potent and orally-active JAK2 in...or patients with chronic idiopathic myelofibrosis ...ate the safety and tolerability of SB1518 in patie...tients. The Phase 1 part of the study will assess...
(Date:12/1/2008)...OUTH MEETING, Pa., Dec. 1 /PRNewswire-FirstCall/ -...ounced that dosing of subjects has begun in study ...dose Phase 1b study of trodusquemine (MSI-1436) in...s a novel therapeutic for the treatment of type 2 ...ipherally to regulate insulin and leptin pathways ...
(Date:11/30/2008)... , CHICAGO, Dec. 1 ...d cerebral blood flow and a greater number of smal...s presented today at the annual meeting of the Rad..., The study, conducted at the University of No...to compare brain scans of older adults who exercis...
(Date:11/26/2008)...ESTER, Minn., Nov. 26 C...d are at significantly increased risk of developin...findings of a Mayo Clinic study published this mo...erican Academy of Pediatrics. , , The retro... patients with strabismus (misaligned eyes) and co...
Breaking Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Eye Divergence in Children Triples Risk of Mental Illness 2Funerary monument reveals Iron Age belief that the soul lived in the stone 29979 1Funerary monument reveals Iron Age belief that the soul lived in the stone 29979 2Funerary monument reveals Iron Age belief that the soul lived in the stone 29979 3Funerary monument reveals Iron Age belief that the soul lived in the stone 29979 4International team discovers gene associated with epilepsy 5914 1International team discovers gene associated with epilepsy 5914 2A big bunch of tomatoes 3F 5912 1A big bunch of tomatoes 3F 5912 2Dr Gail Naughton Speaks on Histogen 26apos 3Bs Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medi 9224 1Dr Gail Naughton Speaks on Histogen 26apos 3Bs Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medi 9224 2Dr Gail Naughton Speaks on Histogen 26apos 3Bs Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medi 9224 3
...phoma Reported,Today at ASCO Annual Meeting, PHILA...line plc,announced today long-term efficacy data f...f frontline treatment with the BEXXAR(R),Therapeut...ab) in,76 patients with newly diagnosed advanced f...en was found to induce durable clinical,and molecu...
...07 - Repros,Therapeutics Inc. (NasdaqGM:RPRX) anno...study of Androxal(TM), an oral drug being,develope...h,secondary hypogonadism. Further, Androxal demons... study, compared to,Androgel(R), a cream which is ... Details and Results , This six month, double-blin...
Other Medicine Technology:8-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 2Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 3Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 4Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 5
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry.
MONOJECT Red/Yellow Mottled Stopper
BD Vacutainer® Specialty Tubes - Thrombin
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry.
Medicine Products: